TG Therapeutics, Inc. (NASDAQ:TGTX)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research note issued to investors on Tuesday. They currently have a $33.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price objective points to a potential upside of 300.00% from the company’s previous close.

Other research analysts have also issued research reports about the company. SunTrust Banks, Inc. reiterated a “buy” rating and issued a $28.00 target price on shares of TG Therapeutics in a research report on Tuesday, October 3rd. BidaskClub upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 24th. Zacks Investment Research lowered TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. Finally, ValuEngine lowered TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, October 16th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $26.78.

Shares of TG Therapeutics (NASDAQ TGTX) opened at $8.25 on Tuesday. TG Therapeutics has a twelve month low of $4.10 and a twelve month high of $15.35.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.05). The business had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.04 million. TG Therapeutics had a negative return on equity of 151.21% and a negative net margin of 73,217.77%. sell-side analysts anticipate that TG Therapeutics will post -1.79 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “TG Therapeutics, Inc. (TGTX) Given “Buy” Rating at HC Wainwright” was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.watchlistnews.com/tg-therapeutics-inc-tgtx-given-buy-rating-at-hc-wainwright/1702070.html.

Several institutional investors and hedge funds have recently bought and sold shares of TGTX. Legal & General Group Plc raised its stake in shares of TG Therapeutics by 4.1% in the 1st quarter. Legal & General Group Plc now owns 9,801 shares of the biopharmaceutical company’s stock worth $113,000 after buying an additional 384 shares in the last quarter. Fox Run Management L.L.C. bought a new stake in shares of TG Therapeutics in the 2nd quarter worth $156,000. Bank of America Corp DE raised its stake in shares of TG Therapeutics by 11.0% in the 1st quarter. Bank of America Corp DE now owns 14,076 shares of the biopharmaceutical company’s stock worth $164,000 after buying an additional 1,395 shares in the last quarter. HighTower Advisors LLC bought a new stake in shares of TG Therapeutics in the 1st quarter worth $170,000. Finally, BB&T Securities LLC raised its stake in shares of TG Therapeutics by 63.0% in the 2nd quarter. BB&T Securities LLC now owns 16,949 shares of the biopharmaceutical company’s stock worth $170,000 after buying an additional 6,549 shares in the last quarter. 49.58% of the stock is currently owned by institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Analyst Recommendations for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.